Rallybio appoints Wendy K. Chung, M.D., Ph.D., to its Board of Directors

Rallybio Corp

Board size increased from 9 to 10; Dr. Chung fills newly created vacancy effective Aug 1, 2022.
Dr. Chung appointed as Class III director with term expiring at 2024 annual meeting.
She will serve on the Nominating and Corporate Governance Committee.
Compensation follows standard non-employee director policy; no material transactions disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Wendy K. Chung, M.D., Ph.D.

director

RLYB · Rallybio Corp

Effective: 2022-08-01
Filed: August 2, 2022, 7:59 PM ET

the Board increased its size from nine directors to ten directors and appointed Wendy K. Chung, M.D., Ph.D. to serve as a director to fill the newly created vacancy, effective August 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy K. Chung, M.D., Ph.D. was appointed as director at Rallybio Corp.

Action: appointed
Role: director

Exact text from the filing

the Board increased its size from nine directors to ten directors and appointed Wendy K. Chung, M.D., Ph.D. to serve as a director to fill the newly created vacancy, effective August 1, 2022.

View on SEC.gov

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-22-013744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.